Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

9823	Companies
197229	Keywords
128349	Articles
104920	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 09/05/2025 at 07:00, 5 months 4 days ago

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
Newron Pharmaceuticals to present data on evenamide as add-on treatment for schizophrenia at 2025 WCBP. Focus on efficacy, safety, and mechanism of action. Landmark studies showcased

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide WCBP
BRIEF

published on 08/12/2025 at 07:05, 5 months 28 days ago

Newron Initiates Phase III ENIGMA-TRS Study for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Phase III Study TRS Therapy
BRIEF

published on 08/12/2025 at 07:05, 5 months 28 days ago

Newron lance l'étude de phase III ENIGMA-TRS pour la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Étude De Phase III Thérapie TRS
PRESS RELEASE

published on 08/12/2025 at 07:00, 5 months 28 days ago

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 08/11/2025 at 07:05, 5 months 29 days ago

L'Evenamide de Newron Pharmaceuticals s'avère prometteur dans le traitement de la schizophrénie

Newron Pharmaceuticals Traitement De La Schizophrénie Recherche Sur L'évenamide Modulation Du Glutamate Étude De Neuropsychopharmacologie
BRIEF

published on 08/11/2025 at 07:05, 5 months 29 days ago

Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals Schizophrenia Treatment Evenamide Research Glutamate Modulation Neuropsychopharmacology Study
PRESS RELEASE

published on 08/11/2025 at 07:00, 5 months 29 days ago

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Newron Pharmaceuticals notes new preclinical research indicating evenamide may improve schizophrenia-related dysfunction by targeting hippocampal pathology. Study shows potential for novel therapeutic strategy

Schizophrenia Newron Pharmaceuticals Evenamide Preclinical Research Hippocampus
BRIEF

published on 05/12/2025 at 07:05, 8 months 28 days ago

Newron's ENIGMA-TRS Phase III Program Approved for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Treatment-resistant Schizophrenia Glutamatergic Modulation
BRIEF

published on 05/12/2025 at 07:05, 8 months 28 days ago

Le programme ENIGMA-TRS de phase III de Newron approuvé pour le traitement de la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Schizophrénie Résistante Au Traitement Modulation Glutamatergique
PRESS RELEASE

published on 05/12/2025 at 07:00, 8 months 28 days ago

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program

Accesswire

Published on 02/09/2026 at 15:00, 3 hours 39 minutes ago

Gungnir Resources Inc. Announces Management And Board Changes
Published on 02/09/2026 at 14:15, 4 hours 24 minutes ago

White Gold Corp. Appoints Seasoned Mining Executive Donovan Pollitt as Strategic Advisor
Published on 02/09/2026 at 14:00, 4 hours 39 minutes ago

Paymetrex Secures First U.S. License Payment
Published on 02/09/2026 at 14:00, 4 hours 39 minutes ago

Geophysics Converge Ahead of Colosseum Deeper Drill Program
Published on 02/09/2026 at 13:00, 5 hours 39 minutes ago

Eagle Plains' Partner Refined Energy Corp. Mobilizes Geophysical Team to the Dufferin West Project, Saskatchewan

View all ACCESSWIRE

EQS Group

Published on 02/09/2026 at 17:52, 47 minutes ago

EQS-Adhoc: GESCO SE: Burden from the insolvency of a contractual partner
Published on 02/09/2026 at 17:28, 1 hour 10 minutes ago

XTPL intends to raise capital through a share offering; the goal for 2026 is next industrial implementation and launch of ODRA sales
Published on 02/09/2026 at 17:24, 1 hour 15 minutes ago

EQS-Adhoc: net digital AG Likely Exceeds 2025 Annual Forecast for Revenue and Earnings
Published on 02/09/2026 at 16:49, 1 hour 49 minutes ago

RM plc: Holding(s) in Company
Published on 02/09/2026 at 15:58, 2 hours 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Just Group plc

Les Echos

Published on 02/09/2026 at 18:00, 39 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 janvier 2026
Published on 02/09/2026 at 17:45, 54 minutes ago

Declaration of voting rights at the end of January 2026
Published on 02/09/2026 at 17:45, 54 minutes ago

DAMARTEX / Droits de vote bruts et réels au 31 janvier 2026
Published on 02/09/2026 at 17:45, 54 minutes ago

Déclaration des droits de vote à fin janvier 2026
Published on 02/09/2026 at 17:45, 54 minutes ago

Déclaration des droits de vote à fin janvier 2026

View all LES ECHOS COMFI WIRE